Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.98 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 0.98 |
| ▸ | THRB | P10828 | 10/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.98 |
| ▸ | BLM | P54132 | 9/20 | 0.98 |
| ▸ | RECQL | P46063 | 8/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.98 |
| ▸ | HTT | P42858 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | S100A4 | P26447 | 5/20 | 0.98 |
| ▸ | STAT6 | P42226 | 5/20 | 0.98 |
| ▸ | NPC1 | O15118 | 4/20 | 0.98 |
| ▸ | RAB9A | P51151 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL29367370 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL5323218 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL4838 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20838939 | 0.99 | ECE1 (0.98) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16606206 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL7029978 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16609956 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20541733 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL15159345 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL12257447 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571459-B2 | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents | ONCXERNA THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20180289771-A1 | METHODS FOR TREATING CANCER USING PS-TARGETING ANTIBODIES WITH IMMUNO-ONCOLOGY AGENTS | ONCXERNA THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| US-9421256-B2 | Anti-VEGF antibody compositions and methods | AFFITECH RESEARCH AS (NO) | 2016-08-23 | — | — | US | disclosed |
| US-20130149238-A1 | Anti-VEGF Antibody Compositions and Methods | PEREGRINE PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8394943-B2 | Anti-VEGF antibody compositions and methods | AFFITECH RESEARCH AS (NO) | 2013-03-12 | — | — | US | disclosed |
| US-20120064001-A1 | Anti-VEGF Antibody Compositions and Methods | AFFITECH RESEARCH AS (NO) | 2012-03-15 | — | — | US | disclosed |
| US-20090175791-A1 | Anti-VEGF Antibody Compositions and Methods | PEREGRINE PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289771-A1 | METHODS FOR TREATING CANCER USING PS-TARGETING ANTIBODIES WITH IMMUNO-ONCOLOGY AGENTS | CD47, TP53, CD274 | TOP2A 1072/4885ECE1 2332/4885MUS81 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.